Salix Pharmaceuticals, Inc.

Biotechnology Research Associates, J.v.

Scios Nova, Inc.

California Biotechnology Inc.

Eli Lilly and Company

University of Toronto

Biotechnology Research Partners, Ltd.

University of Chicago

Lorin K Johnson

John A Lewicki

John P Longenecker

Robert M Scarborough

Jeffrey J Seilhamer

William Forbes

Peter Vadas

John H Laragh

Waldemar Pruzanski

Steven A Atlas

Robert M Scarborough, Jr

Enoch Bortey

Jonathan Moss

Marvin H Sleisenger

Brian J McCarthy

Stephana Patton

A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.

Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives

A method of increasing the bioavailability of 5-aminosalicylate compound by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of 5-aminosalicylate compound in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.

The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.

Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

The present invention provides methods of treating diarrhea-associated irritable bowel syndrome (IBS-D) following rifaximin administration.

Methods for treating diarrhea-associated irritable bowel syndrome

Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer

Antibodies which react with the human phospholipase inhibitory protein/apolipoprotein AIV complex and hPIP are provided.

Antibodies for human phospholipase inhibitory protein (hPIP)

Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.

Antibodies that specifically bind to and inhibit human synovial

The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite thereof.

Cloning and expression of the gene encoding human phospholipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.

Recombinant expression system for human anti-inflammatory phospholipase

Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.

Human anti-inflammatory phospholipase inhibitor protein

Compounds and compositions comprising synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.

Linear analogs of atrial natriuretic peptides

Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to diagnositc methods and other applications of sPLA.sub.2.

Synovial phospholipases

Compounds and compositions comprising cyclic synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.

Growing community of inventors

Pleasanton, CA, United States of America

Lorin K Johnson